Chemotherapy in patients ≥80 with advanced non-small cell lung cancer: Combined results from SWOG 0027 and LUN 6

Paul J. Hesketh, Rogerio C. Lilenbaum, Kari Chansky, Afshin Dowlati, Patricia Graham, Robert A. Chapman, John J. Crowley, David R Gandara

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

INTRODUCTION: We report outcomes for the combined cohort of patients ages 80 or older from two chemotherapy trials in advanced non-small cell lung cancer (NSCLC) conducted by the Southwest Oncology Group (S0027) and an investigator-initiated trial (LUN 6). METHODS: Patients with chemotherapy-naïve, stage IIIB/IV NSCLC, ages 70 years or older with a performance status (PS) of 0 or 1, or patients of any age with PS 2, were eligible. Treatment in the S0027 study was 25 mg/m of vinorelbine on days 1 and 8, every 21 days for three cycles, and then 35 mg/m of docetaxel on days 1, 8, and 15, every 28 days for three cycles. Treatment in the LUN 6 study was 30 mg/m of docetaxel on days 1, 8, and 15, every 28 days, or 75 mg/m every 21 days. Of the 228 patients treated, 49 (21.5%; 26 in LUN 6 and 23 in S0027) were ages 80 years or older. Analysis of outcome was conducted in the 80-and-older group and was compared with the under-80 cohort from S0027. RESULTS: Among patients with measurable disease, disease-control rates (partial response + stable disease) were 54% (n = 48) and 46% (n = 89) in the 80-and-older and under-80 groups, respectively. Median survival was 7 and 11 months in PS 0/1 patients in the 80-and-older and under-80 groups, respectively. Median survival was 4 and 5 months in PS 2 patients in the 80-and-older and under-80 groups, respectively. Treatment was well tolerated. Five treatment-related deaths were noted: two (4%) and three (3.4%) in the 80-or-younger and the under-80 groups, respectively. CONCLUSIONS: These chemotherapy regimens were associated with an encouraging disease-control rate (54%) in patients 80 years or older with advanced NSCLC, with good tolerance. Selected octogenarians with advanced NSCLC may benefit from single-agent chemotherapy.

Original languageEnglish (US)
Pages (from-to)494-498
Number of pages5
JournalJournal of Thoracic Oncology
Volume2
Issue number6
DOIs
StatePublished - Jun 2007

Keywords

  • Chemotherapy
  • Non-small cell lung cancer
  • Octogenarians

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Chemotherapy in patients ≥80 with advanced non-small cell lung cancer: Combined results from SWOG 0027 and LUN 6'. Together they form a unique fingerprint.

Cite this